Compare NDLS & KALA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | NDLS | KALA |
|---|---|---|
| Founded | 1995 | 2009 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Restaurants | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 68.7M | 21.8M |
| IPO Year | 2013 | 2017 |
| Metric | NDLS | KALA |
|---|---|---|
| Price | $11.54 | $1.02 |
| Analyst Decision | Hold | Buy |
| Analyst Count | 1 | 3 |
| Target Price | N/A | ★ $31.50 |
| AVG Volume (30 Days) | 31.0K | ★ 199.5K |
| Earning Date | 05-06-2026 | 04-15-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 67.39 |
| EPS | N/A | ★ N/A |
| Revenue | ★ $495,089,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ 0.37 | N/A |
| 52 Week Low | $0.47 | $0.07 |
| 52 Week High | $16.10 | $20.58 |
| Indicator | NDLS | KALA |
|---|---|---|
| Relative Strength Index (RSI) | 37.85 | 31.47 |
| Support Level | $10.63 | $0.55 |
| Resistance Level | $13.95 | $1.81 |
| Average True Range (ATR) | 1.06 | 0.27 |
| MACD | -0.40 | -0.15 |
| Stochastic Oscillator | 2.87 | 4.68 |
Noodles & Co is a restaurant concept offering lunch and dinner within the fast-casual segment of the restaurant industry. The company's menu includes a variety of cooked-to-order dishes, including noodles and pasta, soups, salads and appetizers. The company also provides dining, pick-up and delivery services. It is focused on offering customers flavorful, cooked-to-order dishes in a warm and welcoming environment at an attractive value. It has approximately 340 company-owned restaurants and 83 franchise restaurants in 31 states.
Kala Bio Inc is a clinical-stage biopharmaceutical company dedicated to the research, development and commercialization of inventive therapies for rare and severe diseases of the front and back of the eye. It main product candidate, KPI-012, is a human MSC-S, which contains numerous human-derived biofactors, such as growth factors, protease inhibitors, matrix proteins, and neurotrophic factors that can potentially correct the impaired corneal healing that is an underlying etiology of multiple severe ocular diseases. Its MSC-S platform is for retinal degenerative diseases, such as Retinitis Pigmentosa and Stargardt Disease.